View Future GrowthBotanix Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Botanix Pharmaceuticals 의 수입은 연평균 -57.1%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.7%의 비율로 증가했습니다. 매출은 연평균 20.6%의 비율로 증가해 왔습니다.핵심 정보-57.10%순이익 성장률-41.44%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률20.56%자기자본이익률-164.28%순이익률-404.72%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 20Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,341,646 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 68,991,667 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options공시 • Apr 10Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 247,994,473 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 406,698,517 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,333,333 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Feb 17+ 1 more updateBotanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 83,333,334 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options공시 • Aug 30Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. Australia공시 • Aug 25Botanix Pharmaceuticals Limited Appoints Dr. Patricia Walker to the Board, Effective August 25, 2025Botanix Pharmaceuticals Limited appointed Dr Patricia Walker, MD, PhD, to their Board of Directors, effective 25 August 2025. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies. Her impactful thought leadership in dermatology is readily apparent with over 60 publications in medical and scientific journals and an outstanding number of learned lectures to her credit. Dr Walker is the recipient of over two dozen academic and professional honours. She brings a wealth of knowledge in drug development for key dermatology products, including Tazorac®, Botox Cosmetic, Juvéderm®, Hylaform®, Captique®, Lap-Band®, Inamed Silicone gel-filled breast implants, and Kybella from her engagements with Allergan, Allergan Medical Aesthetics, Inamed, and Kythera Biopharmaceuticals. Dr Walker also led the development of Botanix's lead product, SofdraTM (sofpironium) topical gel, 12.45% from a preclinical asset to Phase 3 prior to its acquisition by Botanix. Dr Walker previously served as Chief Medical Advisor for Botanix Pharmaceuticals through her consulting company, Walker Consulting, which continues to work with prominent dermatology pharmaceutical companies.Dr Walker completed her medical degree and dermatology residency training at the University of Iowa College of Medicine. She also completed a prestigious research fellowship at the National Institute of Health's Dermatology Branch. Dr Walker put her experience to work teaching the next generation of dermatologists as a member of the Clinical Faculty, Department of Dermatology, University of California, Irvine. Dr Walker has shown a great passion for the oversight of research and new product development all stages from discovery to global market approvals. She is also experienced in securing corporate financing, product licenses, joint development efforts and initial public offerings.공시 • Jun 10Botanix Pharmaceuticals Limited announced that it expects to receive AUD 48 million in funding from Kreos Capital VII (Uk) LimitedBotanix Pharmaceuticals Limited announced that it has entered into a documentation with Kreos Capital VII (UK) Limited and its related entity Kreos Capital for a loan facility of A$48 million on June 10, 2025. The Facility provides for an initial tranche of ~A$31 million, available upon closing and anticipated to be drawn down today (Tranche A) and a further ~A$15.5 million (Tranche B) available to be drawn down up to and including 1 October 2026 subject to draw down conditions. The company will issue warrants to acquire shares each with an exercise price of A$0.33 and with an expiry date five years from the date of issue, subject to the terms of the Warrant instrument. 3,030,303 Warrants will be issued on the Tranche A drawdown of the Facility and a further 1,515,151 Warrants will be issued on satisfaction of the Tranche B drawdown conditions.공시 • Apr 24Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct Listing공시 • Apr 15Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct Listing공시 • Oct 03Botanix Pharmaceuticals Limited Announces Management AppointmentsBotanix Pharmaceuticals Limited announced the appointment of Kevin Wojciechowski Head of HCP Marketing and Sales Training Mr. Wojciechowski joins the company from Avalere Health after being the Executive Director of Marketing and Sales Training at Journey Medical Corporation as well as Senior Product Marketing Manager with Medicis, amongst other senior sales training and field operations management roles with Stryker, Cephalon and J&J. Darin Van Arsdalen Director of Sales Operations Mr. Van Arsdalen comes to the company with previous experience at Incyte, Strata Skin Sciences, Encore Dermatology and Graceway Pharmaceuticals where he held senior sales operations and planning roles responsible for forecasting, field operations, alignments and data management. With more than 20 years specialised experience in sales force optimisation, Mr. Van Arsdalen will be heavily involved in development of tools for reporting around the commercialisation of Sofdra.공시 • Sep 10Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. Australia공시 • Jun 28Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 233,333,334 Price\Range: AUD 0.3 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing공시 • Jan 30Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024, at 10:00 W. Australia Standard Time. Location: BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street Perth Western Australia Australia Agenda: To consider ratification of issue of Placement Shares to sophisticated and professional investors; to consider ratification of issue of Fee Options to Euroz Hartleys Limited (or its nominee(s)); and to discuss other matters.공시 • Nov 29Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 103,846,154 Price\Range: AUD 0.13 Discount Per Security: AUD 0.0078 Transaction Features: Subsequent Direct Listing공시 • Aug 31Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023, at 09:00 W. Australia Standard Time. Location: the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth Western Australia Australia Agenda: To consider the re-election of directors.공시 • Aug 25Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive OfficerBotanix Pharmaceuticals Limited announced that Dr. Howie McKibbon has been appointed as Chief Executive Officer of the Company, following his promotion from Chief Operating Officer. No changes to the Board have been made as a result of this appointment and the appointment is effective 24 August 2023 (Arizona time). Dr. McKibbon was also previously the Chief Commercial Officer for Botanix, and this new promotion reflects both his extensive 25 year experience in the pharmaceutical industry, as well as his development under the guidance of Executive Chairman Vince Ippolito, at Botanix and previous successful dermatology companies, such as Dermavant Sciences, Anacor and Medicis. Dr. McKibbon is based in Phoenix, Arizona, where Botanix has recently expanded its commercial operations. Prior to his roles with Botanix, Dr. McKibbon held the role of Senior Vice-President, Worldwide Commercial Operations at Dermavant Science, where he transitioned Dermavant from a subsidiary, to a fully functioning independent dermatology company and was integral in the acquisition of the product. Before that as Senior Vice President, Sales & Marketing, he built the commercial organization, led the cross-functional launch teams and sat on the clinical development team at Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company acquired by Pfizer for USD 5.2 billion in 2016. Prior to Anacor, Dr. McKibbon was Vice-President, Dermatology and Immunology at Medicis Pharmaceuticals and helped grow Medicis to be the largest independent dermatology company in the world, when it was acquired by Bausch Health for USD 2.6 billion in 2012. His background also includes cross-functional leadership positions across portfolios of neuroscience and oncology brands, at Cephalon and Wyeth Pharmaceuticals. Over the course of his career, Dr. McKibbon has launched more than 15 branded products, managed over thirty dermatology products, and played a significant role in two of the largest dermatology acquisitions with combined valuations of USD 7.8 billion. He holds a B.A. in History from the University of South Florida, an MBA from Mercer University's Stetson School of Business and Economics, and a Doctor of Pharmacy from Mercer University's Southern School of Pharmacy.공시 • Aug 18Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023, at 09:00 W. Australia Standard Time. Location: offices of Gilbert + Tobin, Level 16, Brookfield Place Tower 2, 123 St Georges Terrace Perth Western Australia Australia Agenda: To consider ratification of issue of April Placement Shares to institutional and sophisticated investors; to ratify issue of July Placement Shares to institutional and sophisticated investors; and to ratify issue of Fee Options.매출 및 비용 세부 내역Botanix Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:BXPH.F 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2522-8996030 Sep 2514-8889030 Jun 256-8683031 Mar 254-6360031 Dec 242-3937030 Sep 242-2725030 Jun 242-1412031 Mar 241-1210031 Dec 230-108030 Sep 232-107030 Jun 234-96031 Mar 235-106031 Dec 226-116030 Sep 225-125030 Jun 223-135031 Mar 221-124031 Dec 210-114030 Sep 213-73030 Jun 217-33031 Mar 217-64031 Dec 207-95030 Sep 207-138030 Jun 208-1710031 Mar 208-1810031 Dec 198-2010030 Sep 196-187030 Jun 195-175031 Mar 195-153031 Dec 185-132030 Sep 183-122030 Jun 182-112031 Mar 182-82031 Dec 172-62030 Sep 171-51030 Jun 170-51031 Dec 160-310양질의 수익: BXPH.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: BXPH.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BXPH.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 57.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BXPH.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BXPH.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BXPH.F는 현재 수익성이 없으므로 자본 수익률이 음수(-164.28%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 04:06종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Botanix Pharmaceuticals Limited는 2명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Madeleine WilliamsCanaccord GenuityJoseph PantginisH.C. Wainwright & Co.
공시 • Apr 20Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,341,646 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 68,991,667 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options
공시 • Apr 10Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 247,994,473 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 406,698,517 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,333,333 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Feb 17+ 1 more updateBotanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 83,333,334 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options
공시 • Aug 30Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. Australia
공시 • Aug 25Botanix Pharmaceuticals Limited Appoints Dr. Patricia Walker to the Board, Effective August 25, 2025Botanix Pharmaceuticals Limited appointed Dr Patricia Walker, MD, PhD, to their Board of Directors, effective 25 August 2025. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies. Her impactful thought leadership in dermatology is readily apparent with over 60 publications in medical and scientific journals and an outstanding number of learned lectures to her credit. Dr Walker is the recipient of over two dozen academic and professional honours. She brings a wealth of knowledge in drug development for key dermatology products, including Tazorac®, Botox Cosmetic, Juvéderm®, Hylaform®, Captique®, Lap-Band®, Inamed Silicone gel-filled breast implants, and Kybella from her engagements with Allergan, Allergan Medical Aesthetics, Inamed, and Kythera Biopharmaceuticals. Dr Walker also led the development of Botanix's lead product, SofdraTM (sofpironium) topical gel, 12.45% from a preclinical asset to Phase 3 prior to its acquisition by Botanix. Dr Walker previously served as Chief Medical Advisor for Botanix Pharmaceuticals through her consulting company, Walker Consulting, which continues to work with prominent dermatology pharmaceutical companies.Dr Walker completed her medical degree and dermatology residency training at the University of Iowa College of Medicine. She also completed a prestigious research fellowship at the National Institute of Health's Dermatology Branch. Dr Walker put her experience to work teaching the next generation of dermatologists as a member of the Clinical Faculty, Department of Dermatology, University of California, Irvine. Dr Walker has shown a great passion for the oversight of research and new product development all stages from discovery to global market approvals. She is also experienced in securing corporate financing, product licenses, joint development efforts and initial public offerings.
공시 • Jun 10Botanix Pharmaceuticals Limited announced that it expects to receive AUD 48 million in funding from Kreos Capital VII (Uk) LimitedBotanix Pharmaceuticals Limited announced that it has entered into a documentation with Kreos Capital VII (UK) Limited and its related entity Kreos Capital for a loan facility of A$48 million on June 10, 2025. The Facility provides for an initial tranche of ~A$31 million, available upon closing and anticipated to be drawn down today (Tranche A) and a further ~A$15.5 million (Tranche B) available to be drawn down up to and including 1 October 2026 subject to draw down conditions. The company will issue warrants to acquire shares each with an exercise price of A$0.33 and with an expiry date five years from the date of issue, subject to the terms of the Warrant instrument. 3,030,303 Warrants will be issued on the Tranche A drawdown of the Facility and a further 1,515,151 Warrants will be issued on satisfaction of the Tranche B drawdown conditions.
공시 • Apr 24Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct Listing
공시 • Apr 15Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct Listing
공시 • Oct 03Botanix Pharmaceuticals Limited Announces Management AppointmentsBotanix Pharmaceuticals Limited announced the appointment of Kevin Wojciechowski Head of HCP Marketing and Sales Training Mr. Wojciechowski joins the company from Avalere Health after being the Executive Director of Marketing and Sales Training at Journey Medical Corporation as well as Senior Product Marketing Manager with Medicis, amongst other senior sales training and field operations management roles with Stryker, Cephalon and J&J. Darin Van Arsdalen Director of Sales Operations Mr. Van Arsdalen comes to the company with previous experience at Incyte, Strata Skin Sciences, Encore Dermatology and Graceway Pharmaceuticals where he held senior sales operations and planning roles responsible for forecasting, field operations, alignments and data management. With more than 20 years specialised experience in sales force optimisation, Mr. Van Arsdalen will be heavily involved in development of tools for reporting around the commercialisation of Sofdra.
공시 • Sep 10Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. Australia
공시 • Jun 28Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 233,333,334 Price\Range: AUD 0.3 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing
공시 • Jan 30Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024, at 10:00 W. Australia Standard Time. Location: BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street Perth Western Australia Australia Agenda: To consider ratification of issue of Placement Shares to sophisticated and professional investors; to consider ratification of issue of Fee Options to Euroz Hartleys Limited (or its nominee(s)); and to discuss other matters.
공시 • Nov 29Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 103,846,154 Price\Range: AUD 0.13 Discount Per Security: AUD 0.0078 Transaction Features: Subsequent Direct Listing
공시 • Aug 31Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023, at 09:00 W. Australia Standard Time. Location: the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth Western Australia Australia Agenda: To consider the re-election of directors.
공시 • Aug 25Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive OfficerBotanix Pharmaceuticals Limited announced that Dr. Howie McKibbon has been appointed as Chief Executive Officer of the Company, following his promotion from Chief Operating Officer. No changes to the Board have been made as a result of this appointment and the appointment is effective 24 August 2023 (Arizona time). Dr. McKibbon was also previously the Chief Commercial Officer for Botanix, and this new promotion reflects both his extensive 25 year experience in the pharmaceutical industry, as well as his development under the guidance of Executive Chairman Vince Ippolito, at Botanix and previous successful dermatology companies, such as Dermavant Sciences, Anacor and Medicis. Dr. McKibbon is based in Phoenix, Arizona, where Botanix has recently expanded its commercial operations. Prior to his roles with Botanix, Dr. McKibbon held the role of Senior Vice-President, Worldwide Commercial Operations at Dermavant Science, where he transitioned Dermavant from a subsidiary, to a fully functioning independent dermatology company and was integral in the acquisition of the product. Before that as Senior Vice President, Sales & Marketing, he built the commercial organization, led the cross-functional launch teams and sat on the clinical development team at Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company acquired by Pfizer for USD 5.2 billion in 2016. Prior to Anacor, Dr. McKibbon was Vice-President, Dermatology and Immunology at Medicis Pharmaceuticals and helped grow Medicis to be the largest independent dermatology company in the world, when it was acquired by Bausch Health for USD 2.6 billion in 2012. His background also includes cross-functional leadership positions across portfolios of neuroscience and oncology brands, at Cephalon and Wyeth Pharmaceuticals. Over the course of his career, Dr. McKibbon has launched more than 15 branded products, managed over thirty dermatology products, and played a significant role in two of the largest dermatology acquisitions with combined valuations of USD 7.8 billion. He holds a B.A. in History from the University of South Florida, an MBA from Mercer University's Stetson School of Business and Economics, and a Doctor of Pharmacy from Mercer University's Southern School of Pharmacy.
공시 • Aug 18Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023, at 09:00 W. Australia Standard Time. Location: offices of Gilbert + Tobin, Level 16, Brookfield Place Tower 2, 123 St Georges Terrace Perth Western Australia Australia Agenda: To consider ratification of issue of April Placement Shares to institutional and sophisticated investors; to ratify issue of July Placement Shares to institutional and sophisticated investors; and to ratify issue of Fee Options.